Pembrolizumab Monotherapy Effective for Rare Melanoma

Pembrolizumab led to a dramatic overall response rate among patients with unresectable desmoplastic melanoma.
MDedge News

source https://www.medscape.com/viewarticle/990945?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost